Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.66 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201920 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL990277 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL1150080 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL29903285 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL30205136 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL201921 | 1.00 | CYSLTR1 (0.66) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Alcohol SCHEMBL2569564 | 0.97 | CYSLTR1 (0.64) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2886354 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL2886360 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| SCHEMBL28786456 | 0.95 | CYSLTR1 (0.63) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115710221-A | Synthesis method of montelukast sodium intermediate | 宿迁盛基医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-9487487-B2 | Process for preparation of montelukast sodium | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-08 | — | — | US | disclosed |
| US-9487487-B2 | Process for preparation of montelukast sodium | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150299127-A1 | PROCESS FOR PREPARATION OF MONTELUKAST SODIUM | LAURUS LABS LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299127-A1 | PROCESS FOR PREPARATION OF MONTELUKAST SODIUM | LAURUS LABS LIMITED (IN) | 2015-10-22 | — | — | US | disclosed |
| WO-2012077133-A1 | PROCESSES FOR PREPARATION OF MONTELUKAST SODIUM AND PURIFICATION OF DIOL INTERMEDIATE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
| US-20110014107-A1 | Process For Preparing Anhydrous Rare Earth Metal Halides | ARCH PHARMALABS LIMITED (IN) | 2011-01-20 | — | — | US | disclosed |
| US-20110014107-A1 | Process For Preparing Anhydrous Rare Earth Metal Halides | ARCH PHARMALABS LIMITED (IN) | 2011-01-20 | — | — | US | disclosed |
| EP-2118063-B1 | A METHOD FOR THE PREPARATION OF MONTELUKAST | ZENTIVA KS (CZ) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267958-A1 | METHOD FOR ISOLATION AND PURIFICATION OF MONTELUKAST | ZENTIVA K.S. (CZ) | 2010-10-21 | — | — | US | disclosed |
| US-20100267958-A1 | METHOD FOR ISOLATION AND PURIFICATION OF MONTELUKAST | ZENTIVA K.S. (CZ) | 2010-10-21 | — | — | US | disclosed |
| US-20100174083-A1 | METHOD FOR THE PREPARATION OF MONTELUKAST | ZENTIVA K.S. (CZ) | 2010-07-08 | — | — | US | disclosed |
| US-20100174083-A1 | METHOD FOR THE PREPARATION OF MONTELUKAST | ZENTIVA K.S. (CZ) | 2010-07-08 | — | — | US | disclosed |
| WO-2009138993-A1 | A PROCESS FOR PREPARATION OF MONTELUKAST SODIUM SALT | MACLEODS PHARMACEUTICALS LIMITED (IN) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009006861-A2 | A METHOD FOR ISOLATION AND PURIFICATION OF MONTELUKAST | ZENTIVA, A.S. (CZ) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008083635-A1 | A METHOD FOR THE PREPARATION OF MONTELUKAST | ZENTIVA, A.S. (CZ) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008058118-A2 | PREPARATION OF MONTELUKAST AND ITS SALTS | DR. REDDY'S LABORTORIES, LTD. (IN) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299127-A1 | PROCESS FOR PREPARATION OF MONTELUKAST SODIUM | CMA1, MPST, CYSLTR2 | CYSLTR1 5/4885CYP2C8 788/4885CYSLTR2 3/4885 |
| US-20100267958-A1 | METHOD FOR ISOLATION AND PURIFICATION OF MONTELUKAST | CMA1, LTC4S, SRMS | CYSLTR1 10/4885CYP2C8 472/4885CYSLTR2 7/4885 |
| US-20100174083-A1 | METHOD FOR THE PREPARATION OF MONTELUKAST | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR1 2/4885CYP2C8 180/4885CYSLTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.